====== Preliminary Report - ID Mapping ======
Traditionally the BioGRID repository has required that all curated data map to a peer-reviewed Pubmed ID before public release. With the rapidly evolving global health crisis of COVID-19, we've decided to temporarily suspend that requirement in order to more rapidly curate publications released on platforms such as **[[https://www.biorxiv.org/|BiorXiv]]** and provide that data to the research community. As a result, some of our download files currently require a Pubmed ID to output correctly (such as PSI-MI TAB, BioGRID TAB2, and PSI-MI XML). We recommend anyone wanting to get the most accurate download available to please use our newest **[[:biogrid_tab_version_3.0|TAB3 format]]** instead.

In order to maintain compatibility, we've temporarily assigned new custom IDs in place of Pubmed IDs for each of these publications. So, if you see one of these IDs, you can use the following listing to determine the associated DOI for each.

**WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

^  Custom ID  ^  DOI  ^  AUTHOR  ^ DATASET  ^
|  **888800000002**  |  **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]**  |  Gao T (2020)  | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]**  |
|  **888800000003**  |  **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]**  |  Sun C (2020)  | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]**  |
|  **888800000005**  |  **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]**  |  Wang K (2020)  | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]**  |
|  **888800000006**  |  **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]**  |  Zhou Q (2020)  | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]**  |
|  **888800000007**  |  **[[https://doi.org/10.1101/2020.02.26.964882|10.1101/2020.02.26.964882]]**  |  Jin Z (2020)  | **[[https://thebiogrid.org/221186/publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]**  |
|  **888800000008**  |  **[[https://doi.org/10.1101/2020.03.29.013490|10.1101/2020.03.29.013490]]**  |  Wang C (2020)  | **[[https://thebiogrid.org/221195/publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]**  |
|  **888800000009**  |  **[[https://doi.org/10.1101/2020.03.25.996348|10.1101/2020.03.25.996348]]**  |  Dai W (2020)  | **[[https://thebiogrid.org/221196/publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]**  |
|  **888800000010**  |  **[[https://doi.org/10.1101/2020.03.15.992883|10.1101/2020.03.15.992883]]**  |  Joyce MG (2020)  | **[[https://thebiogrid.org/221197/publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]**  |
|  **888800000011**  |  **[[https://doi.org/10.1101/2020.03.16.993386|10.1101/2020.03.16.993386]]**  |  Gao Y (2020)  | **[[https://thebiogrid.org/221198/publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]**  |
|  **888800000013**  |  **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]**  |  Bestle D (2020)  | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]**  |
|  **888800000018**  |  **[[https://doi.org/10.1101/2020.04.19.049643|10.1101/2020.04.19.049643]]**  |  Zeng X (2020)  | **[[https://thebiogrid.org/221566/publication|Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy]]**  |
|  **888800000020**  |  **[[https://doi.org/10.1101/2020.04.22.046565|10.1101/2020.04.22.046565]]**  |  Liu Y (2020)  | **[[https://thebiogrid.org/221568/publication|Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2]]**  |
|  **888800000021**  |  **[[https://doi.org/10.1101/2020.04.21.053017|10.1101/2020.04.21.053017]]**  |  Walker A (2020)  | **[[https://thebiogrid.org/221569/publication|Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases]]**  |
|  **888800000022**  |  **[[https://doi.org/10.1101/2020.04.17.047498|10.1101/2020.04.17.047498]]**  |  Rosas Lemus M (2020)  | **[[https://thebiogrid.org/221570/publication|The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine]]**  |
|  **888800000025**  |  **[[https://doi.org/10.1101/2020.04.29.068890|10.1101/2020.04.29.068890]]**  |  Rut W (2020)  | **[[https://thebiogrid.org/221777/publication|Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design]]**  |
|  **888800000029**  |  **[[https://doi.org/10.1101/2020.05.02.20086876|10.1101/2020.05.02.20086876]]**  |  Zhang D (2020)  | **[[https://thebiogrid.org/221831/publication|Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)]]**  |
|  **888800000031**  |  **[[https://doi.org/10.1101/2020.05.06.079830|10.1101/2020.05.06.079830]]**  |  Zha L (2020)  | **[[https://thebiogrid.org/221833/publication|Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles]]**  |
|  **888800000032**  |  **[[https://doi.org/10.1101/2020.05.02.043554|10.1101/2020.05.02.043554]]**  |  Gunther S (2020)  | **[[https://thebiogrid.org/221835/publication|Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease]]**  |
|  **888800000034**  |  **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]**  |  Liu X (2020)  | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]**  |
|  **888800000035**  |  **[[https://doi.org/10.1101/2020.05.21.109157|10.1101/2020.05.21.109157]]**  |  Lui I (2020)  | **[[https://thebiogrid.org/222215/publication|Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]**  |
|  **888800000036**  |  **[[https://doi.org/10.1101/2020.05.21.107870|10.1101/2020.05.21.107870]]**  |  Partridge LJ (2020)  | **[[https://thebiogrid.org/222216/publication|Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line]]**  |
|  **888800000037**  |  **[[https://doi.org/10.1101/2020.05.13.092478|10.1101/2020.05.13.092478]]**  |  Chiodo F (2020)  | **[[https://thebiogrid.org/222217/publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]**  |
|  **888800000038**  |  **[[https://doi.org/10.1101/2020.05.12.091298|10.1101/2020.05.12.091298]]**  |  Seydoux E (2020)  | **[[https://thebiogrid.org/222218/publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]**  |
|  **888800000040**  |  **[[https://doi.org/10.1101/2020.05.12.092171|10.1101/2020.05.12.092171]]**  |  Zhou X (2020)  | **[[https://thebiogrid.org/222220/publication|Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation]]**  |
|  **888800000041**  |  **[[https://doi.org/10.1101/2020.06.17.156455|10.1101/2020.06.17.156455]]**  |  Stukalov A (2020)  | **[[https://thebiogrid.org/222410/publication|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]**  |
|  **888800000042**  |  **[[https://doi.org/10.1101/2020.06.05.135921|10.1101/2020.06.05.135921]]**  |  Bertoglio F (2020)  | **[[https://thebiogrid.org/222602/publication|SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface]]**  |
|  **888800000043**  |  **[[https://doi.org/10.1101/2020.06.05.135699|10.1101/2020.06.05.135699]]**  |  Moustaqil M (2020)  | **[[https://thebiogrid.org/222603/publication|SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]**  |
|  **888800000046**  |  **[[https://doi.org/10.1101/2020.06.17.158121|10.1101/2020.06.17.158121]]**  |  Cubuk J (2020)  | **[[https://thebiogrid.org/222654/publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]**  |
|  **888800000050**  |  **[[https://doi.org/10.1101/2020.06.07.138677|10.1101/2020.06.07.138677]]**  |  Luan X (2020)  | **[[https://thebiogrid.org/222705/publication|Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]**  |
|  **888800000052**  |  **[[https://doi.org/10.1101/2020.06.06.137513|10.1101/2020.06.06.137513]]**  |  Lou Y (2020)  | **[[https://thebiogrid.org/222707/publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]**  |
|  **888800000054**  |  **[[https://doi.org/10.1101/2020.06.16.155812|10.1101/2020.06.16.155812]]**  |  Li J (2020)  | **[[https://thebiogrid.org/222709/publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]**  |
|  **888800000056**  |  **[[https://doi.org/10.1101/2020.06.16.154708|10.1101/2020.06.16.154708]]**  |  Hanson QM (2020)  | **[[https://thebiogrid.org/223039/publication|Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay]]**  |
|  **888800000063**  |  **[[https://doi.org/10.1101/2020.07.31.230730|10.1101/2020.07.31.230730]]**  |  Cao W (2020)  | **[[https://thebiogrid.org/223096/publication|Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction]]**  |
|  **888800000064**  |  **[[https://doi.org/10.1101/2020.07.24.219857|10.1101/2020.07.24.219857]]**  |  Esparza TJ (2020)  | **[[https://thebiogrid.org/223097/publication|High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme]]**  |
|  **888800000065**  |  **[[https://doi.org/10.1101/2020.07.25.221036|10.1101/2020.07.25.221036]]**  |  Shilts J (2020)  | **[[https://thebiogrid.org/223098/publication|No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor]]**  |
|  **888800000066**  |  **[[https://doi.org/10.1101/2020.07.13.201517|10.1101/2020.07.13.201517]]**  |  Davies JP (2020)  | **[[https://thebiogrid.org/223099/publication|Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies]]**  |
|  **888800000067**  |  **[[https://doi.org/10.1101/2020.07.31.229781|10.1101/2020.07.31.229781]]**  |  Alitongbieke G (2020)  | **[[https://thebiogrid.org/223100/publication|Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2]]**  |
|  **888800000069**  |  **[[https://doi.org/10.1101/2020.07.27.224089|10.1101/2020.07.27.224089]]**  |  Beasley MD (2020)  | **[[https://thebiogrid.org/223102/publication|Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries]]**  |
|  **888800000070**  |  **[[https://doi.org/10.1101/2020.07.29.227462|10.1101/2020.07.29.227462]]**  |  Gao C (2020)  | **[[https://thebiogrid.org/223103/publication|SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors]]**  |
|  **888800000071**  |  **[[https://doi.org/10.1101/2020.07.26.222026|10.1101/2020.07.26.222026]]**  |  Zheng Y (2020)  | **[[https://thebiogrid.org/223104/publication|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling]]**  |
|  **888800000072**  |  **[[https://doi.org/10.1101/2020.07.30.229187|10.1101/2020.07.30.229187]]**  |  Shi W (2020)  | **[[https://thebiogrid.org/223105/publication|A dynamic regulatory interface on SARS-CoV-2 RNA polymerase]]**  |
|  **888800000075**  |  **[[https://doi.org/10.1101/2020.07.15.204404|10.1101/2020.07.15.204404]]**  |  Schmidt N (2020)  | **[[https://thebiogrid.org/223108/publication|A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells]]**  |
|  **888800000076**  |  **[[https://doi.org/10.1101/2020.08.03.234914|10.1101/2020.08.03.234914]]**  |  Cao L (2020)  | **[[https://thebiogrid.org/223109/publication|De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. [DEPRECATED]]]**  |
|  **888800000078**  |  **[[https://doi.org/10.1101/2020.07.17.208959|10.1101/2020.07.17.208959]]**  |  Fu Z (2020)  | **[[https://thebiogrid.org/223111/publication|Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules]]**  |
|  **888800000079**  |  **[[https://doi.org/10.1101/2020.07.31.231282|10.1101/2020.07.31.231282]]**  |  Tee KL (2020)  | **[[https://thebiogrid.org/223112/publication|Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay]]**  |
|  **888800000080**  |  **[[https://doi.org/10.1101/2020.07.25.220806|10.1101/2020.07.25.220806]]**  |  Temerozo JR (2020)  | **[[https://thebiogrid.org/223113/publication|The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.]]**  |
|  **888800000081**  |  **[[https://doi.org/10.1101/2020.08.03.234559|10.1101/2020.08.03.234559]]**  |  Addetia A (2020)  | **[[https://thebiogrid.org/223399/publication|SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98]]**  |
|  **888800000082**  |  **[[https://doi.org/10.1101/2020.08.28.272955|10.1101/2020.08.28.272955]]**  |  Laurent E (2020)  | **[[https://thebiogrid.org/223400/publication|Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms]]**  |
|  **888800000083**  |  **[[https://doi.org/10.1101/2020.08.20.259770|10.1101/2020.08.20.259770]]**  |  Lapointe CP (2020)  | **[[https://thebiogrid.org/223461/publication|Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation]]**  |
|  **888800000084**  |  **[[https://doi.org/10.1101/2020.08.16.252973|10.1101/2020.08.16.252973]]**  |  Han L (2020)  | **[[https://thebiogrid.org/223462/publication|SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways]]**  |
|  **888800000085**  |  **[[https://doi.org/10.1101/2020.08.06.238915|10.1101/2020.08.06.238915]]**  |  Watson A (2020)  | **[[https://thebiogrid.org/223463/publication|Peptide Antidotes to SARS-CoV-2 (COVID-19)]]**  |
|  **888800000086**  |  **[[https://doi.org/10.1101/2020.08.12.247767|10.1101/2020.08.12.247767]]**  |  Yang Z (2020)  | **[[https://thebiogrid.org/223464/publication|Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2]]**  |
|  **888800000087**  |  **[[https://doi.org/10.1101/2020.08.12.246389|10.1101/2020.08.12.246389]]**  |  Risner K (2020)  | **[[https://thebiogrid.org/223465/publication|Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture]]**  |
|  **888800000088**  |  **[[https://doi.org/10.1101/2020.08.08.238469|10.1101/2020.08.08.238469]]**  |  Schoof M (2020)  | **[[https://thebiogrid.org/223466/publication|An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation]]**  |
|  **888800000089**  |  **[[https://doi.org/10.1101/2020.08.14.250258|10.1101/2020.08.14.250258]]**  |  Chen Y (2020)  | **[[https://thebiogrid.org/223467/publication|Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro]]**  |
|  **888800000090**  |  **[[https://doi.org/10.1101/2020.08.09.242917|10.1101/2020.08.09.242917]]**  |  Thepaut M (2020)  | **[[https://thebiogrid.org/223468/publication|DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist]]**  |
|  **888800000093**  |  **[[https://doi.org/10.1101/2020.08.18.256776|10.1101/2020.08.18.256776]]**  |  Andres AD (2020)  | **[[https://thebiogrid.org/223471/publication|SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells]]**  |
|  **888800000094**  |  **[[https://doi.org/10.1101/2020.08.13.249177|10.1101/2020.08.13.249177]]**  |  Carrique L (2020)  | **[[https://thebiogrid.org/223473/publication|The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer]]**  |
|  **888800000095**  |  **[[https://doi.org/10.1101/2020.08.13.248211|10.1101/2020.08.13.248211]]**  |  Baddock HT (2020)  | **[[https://thebiogrid.org/223474/publication|Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification]]**  |
|  **888800000096**  |  **[[https://doi.org/10.1101/2020.08.10.244525|10.1101/2020.08.10.244525]]**  |  Malla TN (2020)  | **[[https://thebiogrid.org/223475/publication|Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals]]**  |
|  **888800000097**  |  **[[https://doi.org/10.1101/2020.08.11.244863|10.1101/2020.08.11.244863]]**  |  Pillon MC (2020)  | **[[https://thebiogrid.org/223476/publication|Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15]]**  |
|  **888800000098**  |  **[[https://doi.org/10.1101/2020.08.12.247338|10.1101/2020.08.12.247338]]**  |  Wang C (2020)  | **[[https://thebiogrid.org/223477/publication|Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection]]**  |
|  **888800000099**  |  **[[https://doi.org/10.1101/2020.08.14.251421|10.1101/2020.08.14.251421]]**  |  Wilamowski M (2020)  | **[[https://thebiogrid.org/223478/publication|Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography]]**  |
|  **888800000100**  |  **[[https://doi.org/10.1101/2020.08.13.248872|10.1101/2020.08.13.248872]]**  |  Wei C (2020)  | **[[https://thebiogrid.org/223479/publication|SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry]]**  |
|  **888800000101**  |  **[[https://doi.org/10.1101/2020.08.14.251207|10.1101/2020.08.14.251207]]**  |  Heaton BE (2020)  | **[[https://thebiogrid.org/223480/publication|SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2]]**  |
|  **888800000103**  |  **[[https://doi.org/10.1101/2020.08.09.242867|10.1101/2020.08.09.242867]]**  |  Gai J (2020)  | **[[https://thebiogrid.org/223482/publication|A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential]]**  |
|  **888800000104**  |  **[[https://doi.org/10.1101/2020.09.03.282103|10.1101/2020.09.03.282103]]**  |  Samavarchi-Tehrani P (2020)  | **[[https://thebiogrid.org/223517/publication|A SARS-CoV-2 - host proximity interactome]]**  |
|  **888800000105**  |  **[[https://doi.org/10.1101/2020.09.09.287508|10.1101/2020.09.09.287508]]**  |  Gu Y (2020)  | **[[https://thebiogrid.org/223561/publication|Interaction network of SARS-CoV-2 with host receptome through spike protein]]**  |
|  **888800000106**  |  **[[https://doi.org/10.1101/2020.08.29.273441|10.1101/2020.08.29.273441]]**  |  Bojadzic D (2020)  | **[[https://thebiogrid.org/223562/publication|Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19]]**  |
|  **888800000107**  |  **[[https://doi.org/10.1101/2020.09.04.282558|10.1101/2020.09.04.282558]]**  |  Bouwman KM (2020)  | **[[https://thebiogrid.org/223563/publication|Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins]]**  |
|  **888800000108**  |  **[[https://doi.org/10.1101/2020.08.28.271601|10.1101/2020.08.28.271601]]**  |  Dash P (2020)  | **[[https://thebiogrid.org/223564/publication|Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor]]**  |
|  **888800000109**  |  **[[https://doi.org/10.1101/2020.08.28.269175|10.1101/2020.08.28.269175]]**  |  St-Germain JR (2020)  | **[[https://thebiogrid.org/223565/publication|A SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research]]**  |
|  **888800000111**  |  **[[https://doi.org/10.1101/2020.09.04.280081|10.1101/2020.09.04.280081]]**  |  Qiang X (2020)  | **[[https://thebiogrid.org/223567/publication|Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.]]**  |
|  **888800000112**  |  **[[https://doi.org/10.1101/2020.09.09.287987|10.1101/2020.09.09.287987]]**  |  Durdagi S (2020)  | **[[https://thebiogrid.org/223568/publication|Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing]]**  |
|  **888800000113**  |  **[[https://doi.org/10.1101/2020.09.01.277954|10.1101/2020.09.01.277954]]**  |  Bartolome A (2020)  | **[[https://thebiogrid.org/223569/publication|Angiotensin converting enzyme 2 is a novel target of the secretase complex]]**  |
|  **888800000115**  |  **[[https://doi.org/10.1101/2020.09.09.289488|10.1101/2020.09.09.289488]]**  |  Kotani N (2020)  | **[[https://thebiogrid.org/223571/publication|Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry]]**  |
|  **888800000116**  |  **[[https://doi.org/10.1101/2020.08.27.270637|10.1101/2020.08.27.270637]]**  |  Flower TG (2020)  | **[[https://thebiogrid.org/223572/publication|Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion]]**  |
|  **888800000117**  |  **[[https://doi.org/10.1101/2020.09.21.307439|10.1101/2020.09.21.307439]]**  |  Wang X (2020)  | **[[https://thebiogrid.org/223769/publication|Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution]]**  |
|  **888800000118**  |  **[[https://doi.org/10.1101/2020.09.14.295956|10.1101/2020.09.14.295956]]**  |  Lin C (2020)  | **[[https://thebiogrid.org/223770/publication|Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction]]**  |
|  **888800000119**  |  **[[https://doi.org/10.1101/2020.09.16.297366|10.1101/2020.09.16.297366]]**  |  Sagar S (2020)  | **[[https://thebiogrid.org/223771/publication|Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells]]**  |
|  **888800000120**  |  **[[https://doi.org/10.1101/2020.09.18.301952|10.1101/2020.09.18.301952]]**  |  Xiao T (2020)  | **[[https://thebiogrid.org/223772/publication|A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro]]**  |
|  **888800000121**  |  **[[https://doi.org/10.1101/2020.09.16.297945|10.1101/2020.09.16.297945]]**  |  Meyer B (2020)  | **[[https://thebiogrid.org/223773/publication|Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing]]**  |
|  **888800000122**  |  **[[https://doi.org/10.1101/2020.09.22.308338|10.1101/2020.09.22.308338]]**  |  Wagner TR (2020)  | **[[https://thebiogrid.org/223774/publication|NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response]]**  |
|  **888800000123**  |  **[[https://doi.org/10.1101/2020.09.20.297242|10.1101/2020.09.20.297242]]**  |  Ren W (2020)  | **[[https://thebiogrid.org/223775/publication|Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry]]**  |
|  **888800000124**  |  **[[https://doi.org/10.1101/2020.09.13.295691|10.1101/2020.09.13.295691]]**  |  Olaleye OA (2020)  | **[[https://thebiogrid.org/223776/publication|Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.]]**  |
|  **888800000125**  |  **[[https://doi.org/10.1101/2020.09.16.300319|10.1101/2020.09.16.300319]]**  |  Tada T (2020)  | **[[https://thebiogrid.org/223777/publication|A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture]]**  |
|  **888800000126**  |  **[[https://doi.org/10.1101/2020.09.16.299891|10.1101/2020.09.16.299891]]**  |  Higuchi Y (2020)  | **[[https://thebiogrid.org/223778/publication|High affinity modified ACE2 receptors prevent SARS-CoV-2 infection]]**  |
|  **888800000127**  |  **[[https://doi.org/10.1101/2020.09.16.20190694|10.1101/2020.09.16.20190694]]**  |  Ichimura T (2020)  | **[[https://thebiogrid.org/223779/publication|KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney]]**  |
|  **888800000128**  |  **[[https://doi.org/10.1101/2020.11.04.361154|10.1101/2020.11.04.361154]]**  |  de Vries (2020)  | **[[https://thebiogrid.org/225841/publication|Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets]]**  |
|  **888800000129**  |  **[[https://doi.org/10.1101/2020.10.13.336800|10.1101/2020.10.13.336800]]**  |  Yan R (2020)  | **[[https://thebiogrid.org/225985/publication|Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies]]**  |
|  **888800000130**  |  **[[https://doi.org/10.1101/2020.09.27.315796|10.1101/2020.09.27.315796]]**  |  Bauer MS (2020)  | **[[https://thebiogrid.org/225986/publication|A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force]]**  |
|  **888800000131**  |  **[[https://doi.org/10.1101/2020.10.06.328112|10.1101/2020.10.06.328112]]**  |  Lutomski CA (2020)  | **[[https://thebiogrid.org/225987/publication|Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation]]**  |
|  **888800000132**  |  **[[https://doi.org/10.1101/2020.10.31.363473|10.1101/2020.10.31.363473]]**  |  Stevens BR (2020)  | **[[https://thebiogrid.org/225988/publication|TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney]]**  |
|  **888800000133**  |  **[[https://doi.org/10.1101/2020.10.23.350348|10.1101/2020.10.23.350348]]**  |  Tang X (2020)  | **[[https://thebiogrid.org/225989/publication|Transferrin receptor is another receptor for SARS-CoV-2 entry]]**  |
|  **888800000134**  |  **[[https://doi.org/10.1101/2020.11.04.361576|10.1101/2020.11.04.361576]]**  |  Li W (2020)  | **[[https://thebiogrid.org/225990/publication|Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network]]**  |
|  **888800000135**  |  **[[https://doi.org/10.1101/2020.10.29.352450|10.1101/2020.10.29.352450]]**  |  Bakovic A (2020)  | **[[https://thebiogrid.org/225991/publication|Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2]]**  |
|  **888800000136**  |  **[[https://doi.org/10.1101/2020.10.26.356048|10.1101/2020.10.26.356048]]**  |  Liu G (2020)  | **[[https://thebiogrid.org/225992/publication|ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease]]**  |
|  **888800000137**  |  **[[https://doi.org/10.1101/2020.10.16.342097|10.1101/2020.10.16.342097]]**  |  Gao X (2020)  | **[[https://thebiogrid.org/225993/publication|Duple extinguishment of COVID-19: single compound synergized inhibition of SARS-CoV-2 replication and direct suppression of inflammatory cytokines in vitro/vivo]]**  |
|  **888800000138**  |  **[[https://doi.org/10.1101/2020.10.13.337584|10.1101/2020.10.13.337584]]**  |  Roy A (2020)  | **[[https://thebiogrid.org/225994/publication|ACIS, A Novel KepTide(tm), Binds to ACE-2 Receptor and Inhibits the Infection of SARS-CoV2 Virus in vitro in Primate Kidney Cells: Therapeutic Implications for COVID-19]]**  |
|  **888800000139**  |  **[[https://doi.org/10.1101/2020.10.30.361873|10.1101/2020.10.30.361873]]**  |  Andring JT (2020)  | **[[https://thebiogrid.org/225995/publication|Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes]]**  |
|  **888800000140**  |  **[[https://doi.org/10.1101/2020.10.23.347534|10.1101/2020.10.23.347534]]**  |  Mellott D (2020)  | **[[https://thebiogrid.org/225996/publication|A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells]]**  |
|  **888800000141**  |  **[[https://doi.org/10.1101/2020.10.06.327742|10.1101/2020.10.06.327742]]**  |  Kliche J (2020)  | **[[https://thebiogrid.org/225997/publication|Cytoplasmic short linear motifs in ACE2 and integrin beta3 link SARS-CoV-2 host cell receptors to endocytosis and autophagy]]**  |
|  **888800000142**  |  **[[https://doi.org/10.1101/2020.10.18.344622|10.1101/2020.10.18.344622]]**  |  Chan KK (2020)  | **[[https://thebiogrid.org/225998/publication|An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants]]**  |
|  **888800000143**  |  **[[https://doi.org/10.1101/2020.11.01.363788|10.1101/2020.11.01.363788]]**  |  Sun J (2020)  | **[[https://thebiogrid.org/225999/publication|Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV]]**  |
|  **888800000144**  |  **[[https://doi.org/10.1101/2020.10.30.362335|10.1101/2020.10.30.362335]]**  |  Hu Y (2020)  | **[[https://thebiogrid.org/226000/publication|Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture]]**  |
|  **888800000145**  |  **[[https://doi.org/10.1101/2020.10.11.335299|10.1101/2020.10.11.335299]]**  |  Gobeil S (2020)  | **[[https://thebiogrid.org/226001/publication|D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction]]**  |
|  **888800000146**  |  **[[https://doi.org/10.1101/2020.10.06.327445|10.1101/2020.10.06.327445]]**  |  Flynn RA (2020)  | **[[https://thebiogrid.org/226002/publication|Systematic discovery and functional interrogation of SARS-CoV-2 viral RNA-host protein interactions during infection]]**  |
|  **888800000147**  |  **[[https://doi.org/10.1101/2020.09.24.312553|10.1101/2020.09.24.312553]]**  |  Li Y (2020)  | **[[https://thebiogrid.org/226003/publication|SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes]]**  |
|  **888800000148**  |  **[[https://doi.org/10.1101/2020.10.22.351569|10.1101/2020.10.22.351569]]**  |  Nguyen HT (2020)  | **[[https://thebiogrid.org/226004/publication|Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects]]**  |
|  **888800000149**  |  **[[https://doi.org/10.1101/2020.10.22.351056|10.1101/2020.10.22.351056]]**  |  Bojadzic D (2020)  | **[[https://thebiogrid.org/226005/publication|Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2]]**  |
|  **888800000150**  |  **[[https://doi.org/10.1101/2020.10.08.20209114|10.1101/2020.10.08.20209114]]**  |  Wu F (2020)  | **[[https://thebiogrid.org/226006/publication|Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis]]**  |
|  **888800000151**  |  **[[https://doi.org/10.1101/2020.09.30.317818|10.1101/2020.09.30.317818]]**  |  Hsu AC-Y (2020)  | **[[https://thebiogrid.org/226007/publication|SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro]]**  |
|  **888800000152**  |  **[[https://doi.org/10.1101/2020.11.05.369264|10.1101/2020.11.05.369264]]**  |  Soh WT (2020)  | **[[https://thebiogrid.org/226008/publication|The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN]]**  |
|  **888800000153**  |  **[[https://doi.org/10.1101/2020.12.02.408153|10.1101/2020.12.02.408153]]**  |  Roth A (2020)  | **[[https://thebiogrid.org/226406/publication|LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro]]**  |
|  **888800000154**  |  **[[https://doi.org/10.1101/2020.11.24.20237628|10.1101/2020.11.24.20237628]]**  |  Al Ahmad M (2020)  | **[[https://thebiogrid.org/226407/publication|Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric Current]]**  |
|  **888800000155**  |  **[[https://doi.org/10.1101/2020.12.06.413443|10.1101/2020.12.06.413443]]**  |  Svilenov HL (2020)  | **[[https://thebiogrid.org/226408/publication|Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region]]**  |
|  **888800000156**  |  **[[https://doi.org/10.1101/2020.12.01.406116|10.1101/2020.12.01.406116]]**  |  Tito A (2020)  | **[[https://thebiogrid.org/226409/publication|A pomegranate peel extract as inhibitor of SARS-CoV-2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs]]**  |
|  **888800000157**  |  **[[https://doi.org/10.1101/2020.11.24.393629|10.1101/2020.11.24.393629]]**  |  Wang X (2020)  | **[[https://thebiogrid.org/226410/publication|Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2]]**  |
|  **888800000158**  |  **[[https://doi.org/10.1101/2020.12.03.409441|10.1101/2020.12.03.409441]]**  |  Rossetti GG (2020)  | **[[https://thebiogrid.org/226411/publication|Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens]]**  |
|  **888800000159**  |  **[[https://doi.org/10.1101/2020.11.11.378018|10.1101/2020.11.11.378018]]**  |  Eberle RJ (2020)  | **[[https://thebiogrid.org/226412/publication|The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro]]**  |
|  **888800000160**  |  **[[https://doi.org/10.1101/2020.11.12.378422|10.1101/2020.11.12.378422]]**  |  Guenther S (2020)  | **[[https://thebiogrid.org/226413/publication|Inhibition of SARS-CoV-2 main protease by allosteric drug-binding]]**  |
|  **888800000161**  |  **[[https://doi.org/10.1101/2020.12.06.412759|10.1101/2020.12.06.412759]]**  |  Calistri A (2020)  | **[[https://thebiogrid.org/226414/publication|The new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2]]**  |
|  **888800000162**  |  **[[https://doi.org/10.1101/2020.12.03.409318|10.1101/2020.12.03.409318]]**  |  Bertoglio F (2020)  | **[[https://thebiogrid.org/226415/publication|A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations]]**  |
|  **888800000163**  |  **[[https://doi.org/10.1101/2020.11.06.368191|10.1101/2020.11.06.368191]]**  |  Kraus A (2020)  | **[[https://thebiogrid.org/226416/publication|A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2]]**  |
|  **888800000164**  |  **[[https://doi.org/10.1101/2020.12.23.424149|10.1101/2020.12.23.424149]]**  |  Noske G (2020)  | **[[https://thebiogrid.org/226619/publication|A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process]]**  |
|  **888800000165**  |  **[[https://doi.org/10.1101/2020.12.18.423427|10.1101/2020.12.18.423427]]**  |  Zhao Y (2020)  | **[[https://thebiogrid.org/226620/publication|SARS-CoV-2 spike protein interacts with and activates TLR4]]**  |
|  **888800000166**  |  **[[https://doi.org/10.1101/2020.12.19.423537|10.1101/2020.12.19.423537]]**  |  Kitamura N (2020)  | **[[https://thebiogrid.org/226621/publication|An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity]]**  |
|  **888800000167**  |  **[[https://doi.org/10.1101/2020.12.23.424171|10.1101/2020.12.23.424171]]**  |  Schmitz A (2020)  | **[[https://thebiogrid.org/226622/publication|A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism]]**  |
|  **888800000168**  |  **[[https://doi.org/10.1101/2020.12.31.424961|10.1101/2020.12.31.424961]]**  |  Chen Z (2021)  | **[[https://thebiogrid.org/226623/publication|Comprehensive analysis of the host-virus interactome of SARS-CoV-2]]**  |
|  **888800000169**  |  **[[https://doi.org/10.1101/2020.12.21.423721|10.1101/2020.12.21.423721]]**  |  Avolio E (2020)  | **[[https://thebiogrid.org/226624/publication|The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease]]**  |
|  **888800000170**  |  **[[https://doi.org/10.1101/2020.12.19.423584|10.1101/2020.12.19.423584]]**  |  Garcia-Dorival I (2020)  | **[[https://thebiogrid.org/226625/publication|Identification of NPC1 as a novel SARS-CoV-2 intracellular target]]**  |
|  **888800000171**  |  **[[https://doi.org/10.1101/2020.12.26.424423|10.1101/2020.12.26.424423]]**  |  Durdagi S (2020)  | **[[https://thebiogrid.org/226626/publication|The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies]]**  |
|  **888800000172**  |  **[[https://doi.org/10.1101/2020.12.18.423415|10.1101/2020.12.18.423415]]**  |  Madan T (2020)  | **[[https://thebiogrid.org/226627/publication|A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples]]**  |
|  **888800000173**  |  **[[https://doi.org/10.1101/2020.12.29.424698|10.1101/2020.12.29.424698]]**  |  Yang X (2020)  | **[[https://thebiogrid.org/226628/publication|An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro]]**  |
|  **888800000174**  |  **[[https://doi.org/10.1101/2020.12.20.422820|10.1101/2020.12.20.422820]]**  |  Fiedler S (2020)  | **[[https://thebiogrid.org/226629/publication|In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum]]**  |
|  **888800000175**  |  **[[https://doi.org/10.1101/2020.12.22.422708|10.1101/2020.12.22.422708]]**  |  Shepley-McTaggart A (2020)  | **[[https://thebiogrid.org/226630/publication|SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1]]**  |
|  **888800000176**  |  **[[https://doi.org/10.1101/2020.12.18.423418|10.1101/2020.12.18.423418]]**  |  Hsieh M-H (2020)  | **[[https://thebiogrid.org/226631/publication|Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro]]**  |
|  **888800000177**  |  **[[https://doi.org/10.1101/2020.12.16.422677|10.1101/2020.12.16.422677]]**  |  Kuzikov M (2020)  | **[[https://thebiogrid.org/226632/publication|Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen]]**  |
|  **888800000178**  |  **[[https://doi.org/10.1101/2020.12.30.424801|10.1101/2020.12.30.424801]]**  |  Woo HG (2020)  | **[[https://thebiogrid.org/226633/publication|Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro]]**  |
|  **888800000179**  |  **[[https://doi.org/10.1101/2020.12.26.424422|10.1101/2020.12.26.424422]]**  |  Xu W (2020)  | **[[https://thebiogrid.org/226634/publication|Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening]]**  |
|  **888800000180**  |  **[[https://doi.org/10.1101/2020.12.09.417741|10.1101/2020.12.09.417741]]**  |  Armstrong L (2020)  | **[[https://thebiogrid.org/226635/publication|Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies]]**  |
|  **888800000181**  |  **[[https://doi.org/10.1101/2020.12.29.424682|10.1101/2020.12.29.424682]]**  |  Kuznetsov A (2020)  | **[[https://thebiogrid.org/226636/publication|ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1]]**  |
|  **888800000182**  |  **[[https://doi.org/10.1101/2021.01.21.427657|10.1101/2021.01.21.427657]]**  |  Choi R (2021)  | **[[https://thebiogrid.org/226858/publication|High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.]]**  |
|  **888800000183**  |  **[[https://doi.org/10.1101/2021.01.12.426388|10.1101/2021.01.12.426388]]**  |  Kneller DW (2021)  | **[[https://thebiogrid.org/226859/publication|Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease]]**  |
|  **888800000184**  |  **[[https://doi.org/10.1101/2021.01.17.427000|10.1101/2021.01.17.427000]]**  |  Wan Y (2021)  | **[[https://thebiogrid.org/226860/publication|Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions]]**  |
|  **888800000185**  |  **[[https://doi.org/10.1101/2021.01.19.427194|10.1101/2021.01.19.427194]]**  |  Tian R (2021)  | **[[https://thebiogrid.org/226861/publication|BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2]]**  |
|  **888800000186**  |  **[[https://doi.org/10.1101/2021.01.11.426269|10.1101/2021.01.11.426269]]**  |  Zhu X (2021)  | **[[https://thebiogrid.org/226862/publication|Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody]]**  |
|  **888800000187**  |  **[[https://doi.org/10.1101/2021.01.05.425478|10.1101/2021.01.05.425478]]**  |  Kamle S (2021)  | **[[https://thebiogrid.org/226863/publication|Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19]]**  |
|  **888800000188**  |  **[[https://doi.org/10.1101/2021.01.14.426695|10.1101/2021.01.14.426695]]**  |  Carnell GW (2021)  | **[[https://thebiogrid.org/226864/publication|SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses]]**  |
|  **888800000189**  |  **[[https://doi.org/10.1101/2021.01.13.21249429|10.1101/2021.01.13.21249429]]**  |  Hultstrom M (2021)  | **[[https://thebiogrid.org/226865/publication|Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients]]**  |
|  **888800000190**  |  **[[https://doi.org/10.1101/2021.01.19.427324|10.1101/2021.01.19.427324]]**  |  Suryadevara N (2021)  | **[[https://thebiogrid.org/226866/publication|Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein]]**  |
|  **888800000191**  |  **[[https://doi.org/10.1101/2021.01.11.426218|10.1101/2021.01.11.426218]]**  |  Rapp M (2021)  | **[[https://thebiogrid.org/226867/publication|Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class]]**  |
|  **888800000192**  |  **[[https://doi.org/10.1101/2021.01.07.425745|10.1101/2021.01.07.425745]]**  |  Saramago M (2021)  | **[[https://thebiogrid.org/226868/publication|New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2]]**  |
|  **888800000193**  |  **[[https://doi.org/10.1101/2021.01.12.426042|10.1101/2021.01.12.426042]]**  |  Siniavin AE (2021)  | **[[https://thebiogrid.org/226869/publication|Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor]]**  |
|  **888800000194**  |  **[[https://doi.org/10.1101/2021.01.07.425806|10.1101/2021.01.07.425806]]**  |  Bell BN (2021)  | **[[https://thebiogrid.org/226870/publication|Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library]]**  |
|  **888800000195**  |  **[[https://doi.org/10.1101/2021.01.20.427368|10.1101/2021.01.20.427368]]**  |  Carlos AJ (2021)  | **[[https://thebiogrid.org/226871/publication|GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro]]**  |
|  **888800000196**  |  **[[https://doi.org/10.1101/2021.01.05.425516|10.1101/2021.01.05.425516]]**  |  Verma R (2021)  | **[[https://thebiogrid.org/226872/publication|RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2]]**  |
|  **888800000197**  |  **[[https://doi.org/10.1101/2021.01.29.428890|10.1101/2021.01.29.428890]]**  |  Berndt AJ (2021)  | **[[https://thebiogrid.org/227046/publication|Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii]]**  |
|  **888800000198**  |  **[[https://doi.org/10.1101/2021.01.29.428834|10.1101/2021.01.29.428834]]**  |  Bayarri-Olmos R (2021)  | **[[https://thebiogrid.org/227047/publication|The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization]]**  |
|  **888800000199**  |  **[[https://doi.org/10.1101/2021.02.03.429601|10.1101/2021.02.03.429601]]**  |  Prahlad J (2021)  | **[[https://thebiogrid.org/227048/publication|Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain]]**  |
|  **888800000200**  |  **[[https://doi.org/10.1101/2021.02.03.429625|10.1101/2021.02.03.429625]]**  |  Khalili Yazdi A (2021)  | **[[https://thebiogrid.org/227049/publication|A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex]]**  |
|  **888800000201**  |  **[[https://doi.org/10.1101/2021.02.01.429176|10.1101/2021.02.01.429176]]**  |  Caillet-Saguy C (2021)  | **[[https://thebiogrid.org/227050/publication|Host PDZ-containing proteins targeted by SARS-Cov-2]]**  |
|  **888800000202**  |  **[[https://doi.org/10.1101/2021.02.11.430866|10.1101/2021.02.11.430866]]**  |  Liu H (2021)  | **[[https://thebiogrid.org/227051/publication|A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection]]**  |
|  **888800000203**  |  **[[https://doi.org/10.1101/2021.02.02.429311|10.1101/2021.02.02.429311]]**  |  Ma H (2021)  | **[[https://thebiogrid.org/227052/publication|Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain]]**  |
|  **888800000204**  |  **[[https://doi.org/10.1101/2021.02.19.424337|10.1101/2021.02.19.424337]]**  |  Devkota K (2021)  | **[[https://thebiogrid.org/227053/publication|Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors]]**  |
|  **888800000205**  |  **[[https://doi.org/10.1101/2021.02.13.431008|10.1101/2021.02.13.431008]]**  |  Shen Z (2021)  | **[[https://thebiogrid.org/227054/publication|Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures]]**  |
|  **888800000206**  |  **[[https://doi.org/10.1101/2021.02.17.431617|10.1101/2021.02.17.431617]]**  |  Bollavaram K (2021)  | **[[https://thebiogrid.org/227055/publication|Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V]]**  |
|  **888800000207**  |  **[[https://doi.org/10.1101/2021.01.31.429023|10.1101/2021.01.31.429023]]**  |  Minasov G (2021)  | **[[https://thebiogrid.org/227056/publication|Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16]]**  |
|  **888800000208**  |  **[[https://doi.org/10.1101/2021.02.03.429355|10.1101/2021.02.03.429355]]**  |  Graham C (2021)  | **[[https://thebiogrid.org/227057/publication|Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike]]**  |
|  **888800000209**  |  **[[https://doi.org/10.1101/2021.02.09.430451|10.1101/2021.02.09.430451]]**  |  Spelios MG (2021)  | **[[https://thebiogrid.org/227058/publication|A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding]]**  |
|  **888800000210**  |  **[[https://doi.org/10.1101/2021.02.02.428884|10.1101/2021.02.02.428884]]**  |  Zhang G (2021)  | **[[https://thebiogrid.org/227059/publication|The basis of a more contagious 501Y.V1 variant of SARS-COV-2]]**  |
|  **888800000211**  |  **[[https://doi.org/10.1101/2021.02.16.431021|10.1101/2021.02.16.431021]]**  |  Arutyunova E (2021)  | **[[https://thebiogrid.org/227060/publication|N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro]]**  |
|  **888800000212**  |  **[[https://doi.org/10.1101/2021.02.07.429299|10.1101/2021.02.07.429299]]**  |  Gu C (2021)  | **[[https://thebiogrid.org/227061/publication|A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques]]**  |
|  **888800000213**  |  **[[https://doi.org/10.1101/2021.02.04.429751|10.1101/2021.02.04.429751]]**  |  Slavin M (2021)  | **[[https://thebiogrid.org/227062/publication|Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2]]**  |
|  **888800000214**  |  **[[https://doi.org/10.1101/2021.02.08.430344|10.1101/2021.02.08.430344]]**  |  Zhao H (2021)  | **[[https://thebiogrid.org/227063/publication|Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids]]**  |
|  **888800000215**  |  **[[https://doi.org/10.1101/2021.02.14.431117|10.1101/2021.02.14.431117]]**  |  Tian F (2021)  | **[[https://thebiogrid.org/227064/publication|Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2]]**  |
|  **888800000216**  |  **[[https://doi.org/10.1101/2021.02.17.431755|10.1101/2021.02.17.431755]]**  |  Zhao Y (2021)  | **[[https://thebiogrid.org/227065/publication|SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses]]**  |